22:17:02 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


2025-04-03 Årsstämma 2025
2025-02-26 Bokslutskommuniké 2024
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-01 X-dag ordinarie utdelning NSIS B 2.00 DKK
2024-04-30 Årsstämma 2024
2024-03-04 Extra Bolagsstämma 2024
2024-02-08 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-10-13 X-dag bonusutdelning NSIS B 4.2
2023-08-09 Kvartalsrapport 2023-Q2
2023-04-26 Kvartalsrapport 2023-Q1
2023-03-30 Extra Bolagsstämma 2023
2023-03-03 X-dag ordinarie utdelning NSIS B 6.00 DKK
2023-03-02 Årsstämma 2023
2023-01-26 Bokslutskommuniké 2022
2022-11-03 Kvartalsrapport 2022-Q3
2022-08-11 Kvartalsrapport 2022-Q2
2022-04-27 Kvartalsrapport 2022-Q1
2022-03-17 X-dag ordinarie utdelning NSIS B 5.50 DKK
2022-03-16 Årsstämma 2022
2022-02-01 Bokslutskommuniké 2021
2021-10-27 Kvartalsrapport 2021-Q3
2021-08-12 Kvartalsrapport 2021-Q2
2021-04-27 Kvartalsrapport 2021-Q1
2021-03-12 X-dag ordinarie utdelning NSIS B 5.25 DKK
2021-03-11 Årsstämma 2021
2021-02-02 Bokslutskommuniké 2020
2020-10-21 Kvartalsrapport 2020-Q3
2020-08-12 Kvartalsrapport 2020-Q2
2020-04-29 Kvartalsrapport 2020-Q1
2020-02-27 X-dag ordinarie utdelning NSIS B 5.25 DKK
2020-02-26 Årsstämma 2020
2020-01-23 Bokslutskommuniké 2019
2019-10-23 Kvartalsrapport 2019-Q3
2019-08-08 Kvartalsrapport 2019-Q2
2019-04-24 Kvartalsrapport 2019-Q1
2019-02-28 X-dag ordinarie utdelning NSIS B 5.00 DKK
2019-02-27 Årsstämma 2019
2019-01-24 Bokslutskommuniké 2018
2018-10-24 Kvartalsrapport 2018-Q3
2018-08-10 Kvartalsrapport 2018-Q2
2018-04-25 Kvartalsrapport 2018-Q1
2018-03-14 X-dag ordinarie utdelning NSIS B 4.50 DKK
2018-03-13 Årsstämma 2018
2018-02-07 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-11 Kvartalsrapport 2017-Q2
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-23 X-dag ordinarie utdelning NSIS B 4.00 DKK
2017-02-22 Årsstämma 2017
2017-01-18 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-10 Kvartalsrapport 2016-Q2
2016-04-20 Kvartalsrapport 2016-Q1
2016-02-25 X-dag ordinarie utdelning NSIS B 3.50 DKK
2016-02-24 Årsstämma 2016
2016-01-19 Bokslutskommuniké 2015
2015-10-22 Kvartalsrapport 2015-Q3
2015-08-06 Kvartalsrapport 2015-Q2
2015-04-23 Kvartalsrapport 2015-Q1
2015-02-26 X-dag ordinarie utdelning NSIS B 3.00 DKK
2015-02-25 Årsstämma 2015
2015-01-20 Bokslutskommuniké 2014
2014-10-23 Kvartalsrapport 2014-Q3
2014-08-14 Kvartalsrapport 2014-Q2
2014-04-24 Kvartalsrapport 2014-Q1
2014-02-27 X-dag ordinarie utdelning NSIS B 2.50 DKK
2014-02-26 Årsstämma 2014
2014-01-21 Bokslutskommuniké 2013
2013-10-25 Kvartalsrapport 2013-Q3
2013-08-09 Kvartalsrapport 2013-Q2
2013-04-25 Kvartalsrapport 2013-Q1
2013-03-01 X-dag ordinarie utdelning NSIS B 2.20 DKK
2013-02-28 Årsstämma 2013
2012-10-25 Kvartalsrapport 2012-Q3
2012-08-16 Kvartalsrapport 2012-Q2
2012-04-25 Kvartalsrapport 2012-Q1
2012-03-01 X-dag ordinarie utdelning NSIS B 1.90 DKK
2012-02-29 Årsstämma 2012
2012-01-19 Bokslutskommuniké 2011
2011-11-28 Split NSIS B 1:5
2011-10-28 Kvartalsrapport 2011-Q3
2011-08-11 Kvartalsrapport 2011-Q2
2011-04-29 Kvartalsrapport 2011-Q1
2011-03-03 X-dag ordinarie utdelning NSIS B 8.00 DKK
2011-03-02 Årsstämma 2011
2011-01-21 Bokslutskommuniké 2010
2010-10-28 Kvartalsrapport 2010-Q3
2010-08-12 Kvartalsrapport 2010-Q2
2010-04-29 Kvartalsrapport 2010-Q1
2010-03-04 X-dag ordinarie utdelning NSIS B 5.75 DKK
2010-03-03 Årsstämma 2010
2009-03-05 X-dag ordinarie utdelning NSIS B 5.25 DKK
2008-03-06 X-dag ordinarie utdelning NSIS B 5.00 DKK
2007-03-09 X-dag ordinarie utdelning NSIS B 4.50 DKK
2006-03-02 X-dag ordinarie utdelning NSIS B 4.00 DKK
2005-03-17 X-dag ordinarie utdelning NSIS B 3.50 DKK
2004-03-18 X-dag ordinarie utdelning NSIS B 3.15 DKK
2003-03-20 X-dag ordinarie utdelning NSIS B 2.25 DKK
2002-03-21 X-dag ordinarie utdelning NSIS B 2.00 DKK
2001-03-22 X-dag ordinarie utdelning NSIS B 1.65 DKK


ListaLarge Cap Copenhagen
Novonesis är verksamma inom biokemi. Bolaget utvecklar enzymer och mikroorganismer för industriellt bruk. Enzymerna är ett protein som används inom ett flertal olika branscher, huvudsakligen inom jordbruks- och livsmedelsindustrin. Produkterna används inom livsmedel samt kläder, och försäljning innehas på global nivå, med störst närvaro inom Norden och Europa. Bolaget har sitt huvudkontor i Bagsværd.
2024-02-01 07:59:37

6% organic sales growth in Q4 and 5% for the full year with solid margins and free cash flow generation

As Novozymes just closed the combination with Chr. Hansen on January 29, and the annual report now is expected to be released on February 8, this announcement only contains unaudited numbers. Full audited financial statements as well as non-financial numbers will be released with the annual report on February 8. This result update allows us to provide selected numbers for Novozymes standalone as early as possible.

Ester Baiget, President & CEO: “I am very pleased with our performance in 2023 - a year characterized by changing market demand and inventory adjustments in certain industries. The strength of Novozymes’ diversified portfolio and end-market exposure enables us to capture growth opportunities as they arise, providing a solid overall performance. We delivered organic sales growth of 5% for the year with solid earnings and cash flows. We closed the combination with Chr. Hansen on January 29. Our new company, Novonesis, is better equipped to enable customers further address the ever-increasing needs for healthier lives and a healthier planet supported by our broad portfolio of innovative, value added biosolutions. Thank you to all stakeholders for supporting us in making Novonesis become a reality”.

Sales performance (unaudited)

  • DKK sales growth at 2% (5% org., -3% FX, 0% M&A), Q4 DKK sales growth at 2% (6% org., -4% FX, 0% M&A).
  • 5% organic sales growth driven by broad-based pricing, flat volumes (Q4: ~4% pricing, ~2% volumes):
    • Household Care 5% (Q4: 10%): Growth in developed markets from innovation and increased penetration despite declining in-market detergent volumes. Emerging markets grew from increased penetration of enzymatic solutions. Strong end to the year with high uptake of innovation and penetration.
    • Food, Beverages & Human Health -2% (Q4: -4%): Year characterized by destocking and a one-off in the comparable base (performance flat excluding the one-off). Demanding Q4 year-on-year comparable and timing impact. Human Health soft as well with sequential growth in Q4 over Q3, but with high Q4 comparator from last year.
    • Bioenergy 23% (Q4: 20%): Demand remaining strong across geographies and a broad, differentiated portfolio of solutions for multiple end-markets. ~4% Q4 y/y volume growth in US ethanol production.
    • Grain & Tech Processing -6% (Q4: 2%): Growth in Grain offset by expected softness in tech from reduced sales of solutions for Covid-19 test kits and, additionally, declining demand in textile. Q4 with a less negative textile market and growth in grain.
    • Agriculture, Animal Health & Nutrition 3% (Q4: -7%): Growth driven by performance in Animal Health & Nutrition with strong demand for sustainable yield and health solutions. Performance muted in Q4 following year-end inventory optimization and destocking in value chain.

Financial performance (unaudited)

  • Reported EBIT margin b.s.i. at 25.4% (underlying ~25.5% b.s.i.) for the year and 25.1% in Q4 (underlying ~26% b.s.i.) and negative FX for both periods. Higher input costs partly mitigated by positive pricing taking gross margin to 54.3% with y-o-y and Q4 vs. Q3 improvement.
  • Free cash flow bef. acq. at a solid DKK 2.1 billion for the year, 1 billion higher than in 2022, mainly from lower investments.
  • Solid balance sheet with NIBD/EBITDA ratio of 1.2x.
  • ROIC incl. goodwill b.s.i. solid at 16.5% with higher invested capital year-on-year.
  • Interim dividend of DKK 4.20 per share for January 1 – August 31 period paid on October 17.

Outlook 2023
12M 202312M 2022Q4 2023Q4 2022
Sales growth, organic%4-659611
EBIT margin, b.s.i.*%25-2625.426.425.123.4
ROIC incl. goodwill, b.s.i.*%16-1716.517.9  

*Special items include costs related to the combination with Chr. Hansen

Other key events and information

  • 18 new products launched in 2023, of which 8 in Q4. Of the 18 products, 7 were public (3 in Q4).
  • Site for production of Advanced Protein Solutions in Blair, US, on-line in December. First shipment in January.
  • New company name ‘Novonesis’ announced, and level 3 leadership structure formalized.
  • Combination with Chr. Hansen completed on January 29, 2024 (announcement 02, 2024) following all regulatory approvals received and registrations completed.
  • Novozymes expects to release its 2023 Annual Report on February 8 following the recent approval of the combination with Chr. Hansen.
  • Proforma numbers for Novonesis including revenue, organic revenue growth, key financial numbers as well as 2024 outlook will be provided no later than March 31.
  • Novonesis will host a Capital Markets Day in London on June 18, 2024.
  • Proposed dividend for the period September 1 - December 31, 2023 will be announced by the Board of Directors of Novonesis in connection with the notice to convene at the Annual Shareholders’ Meeting.

Selected key data (unaudited)

  12M 202312M 2022Q4 2023Q4 2022
Sales performance, organic%59611
Household Care%51104
Food, Beverages & Human Health%(2)10(4)16
Grain & Tech Processing%(6)1025
Agriculture, Animal Health & Nutrition%38(7)11
Sales performance, DKK%217218
Gross margin%54.354.654.053.5
EBIT margin%
EBIT before special items*DKKm4,5524,6291,1571,059
EBIT margin before special items*%25.426.425.123.4
Net profitDKKm3,0393,686695877
Net investments excl. acquisitionsDKKm2,0522,862603898
Free cash flow before acquisitionsDKKm2,1001,144519(314)
ROIC, incl. goodwill%14.417.6  
ROIC, incl. goodwill, before special items*%16.517.9  
Special items*DKKm(576)(68)(202)(37)
EPS 10.9213.292.523.19
EPS (diluted) 10.8813.192.513.18
Avg. USD/DKK 689708694730

*Special items include costs related to the combination with Chr. Hansen

Contact information
Investor Relations  
Tobias Bjorklund+45 3077 8682tobb@novozymes.com
Anders Enevoldsen+45 5350 1453adev@novozymes.com

Media Relations
Lina Danstrup+45 3077 0552lind@novozymes.com